PL1698640T3 - Sposób stabilizacji przeciwciała i stabilizowany preparat przeciwciała w postaci roztworu - Google Patents
Sposób stabilizacji przeciwciała i stabilizowany preparat przeciwciała w postaci roztworuInfo
- Publication number
- PL1698640T3 PL1698640T3 PL04773700T PL04773700T PL1698640T3 PL 1698640 T3 PL1698640 T3 PL 1698640T3 PL 04773700 T PL04773700 T PL 04773700T PL 04773700 T PL04773700 T PL 04773700T PL 1698640 T3 PL1698640 T3 PL 1698640T3
- Authority
- PL
- Poland
- Prior art keywords
- antibody
- stabilizing
- stabilized solution
- type
- preparation
- Prior art date
Links
- 230000000087 stabilizing effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003343645 | 2003-10-01 | ||
| EP04773700.2A EP1698640B2 (en) | 2003-10-01 | 2004-10-01 | Method of stabilizing antibody and stabilized solution-type antibody preparation |
| PCT/JP2004/014903 WO2005033143A1 (ja) | 2003-10-01 | 2004-10-01 | 抗体の安定化方法及び安定化された溶液状抗体製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL1698640T3 true PL1698640T3 (pl) | 2016-05-31 |
| PL1698640T5 PL1698640T5 (pl) | 2019-12-31 |
Family
ID=34419308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04773700T PL1698640T5 (pl) | 2003-10-01 | 2004-10-01 | Sposób stabilizacji przeciwciała i stabilizowany preparat przeciwciała w postaci roztworu |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8496930B2 (pl) |
| EP (2) | EP3006463A1 (pl) |
| JP (1) | JP4219932B2 (pl) |
| KR (1) | KR100911091B1 (pl) |
| CN (1) | CN100522998C (pl) |
| AU (1) | AU2004277466C1 (pl) |
| CA (1) | CA2540848C (pl) |
| CY (1) | CY1117215T1 (pl) |
| DK (1) | DK1698640T4 (pl) |
| ES (1) | ES2562912T5 (pl) |
| HU (1) | HUE026793T2 (pl) |
| PL (1) | PL1698640T5 (pl) |
| PT (1) | PT1698640E (pl) |
| SI (1) | SI1698640T2 (pl) |
| WO (1) | WO2005033143A1 (pl) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6914128B1 (en) * | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| US7883704B2 (en) * | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
| DK1698640T4 (da) * | 2003-10-01 | 2019-09-02 | Kyowa Hakko Kirin Co Ltd | Fremgangsmåde til stabilisering af antistof og antistofpræparat som stabiliseret opløsning. |
| WO2006125207A2 (en) * | 2005-05-19 | 2006-11-23 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
| WO2007016562A2 (en) * | 2005-07-29 | 2007-02-08 | Amgen Inc. | Formulations that inhibit protein aggregation |
| BRPI0710826A2 (pt) * | 2006-04-21 | 2011-08-23 | Novartis Ag | composições farmacêuticas de anticorpo anti-cd40 antagonista |
| AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
| AU2008205512B2 (en) * | 2007-01-16 | 2014-06-12 | Abbvie Inc. | Methods for treating psoriasis |
| BRPI0809209A2 (pt) | 2007-03-29 | 2014-09-02 | Abbott Lab | Anticorpos il-12 anti-humanos cristalinos |
| KR20210049186A (ko) * | 2007-11-30 | 2021-05-04 | 애브비 바이오테크놀로지 리미티드 | 단백질 제형 및 이의 제조방법 |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| US8178092B2 (en) | 2008-03-18 | 2012-05-15 | Abbott Laboratories | Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23 |
| CA2742791A1 (en) * | 2008-11-28 | 2010-06-03 | Abbott Laboratories | Stable antibody compositions and methods for stabilizing same |
| SG10201401995UA (en) * | 2009-05-04 | 2014-08-28 | Abbvie Biotechnology Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| CA2764050C (en) * | 2009-06-04 | 2017-02-28 | Alk Ag | Stabilised composition comprising at least one adrenergic compound |
| JP2013504598A (ja) * | 2009-09-14 | 2013-02-07 | アボット・ラボラトリーズ | 乾癬を治療するための方法 |
| AU2011219715B2 (en) | 2010-02-26 | 2014-12-11 | Novo Nordisk A/S | Stable antibody containing compositions |
| ES2765418T3 (es) | 2010-03-01 | 2020-06-09 | Bayer Healthcare Llc | Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI) |
| JP6294075B2 (ja) | 2010-05-28 | 2018-03-14 | ノヴォ ノルディスク アー／エス | 抗体及び防腐剤を含む安定した多用量組成物 |
| CN103282042B (zh) | 2010-09-17 | 2014-12-10 | 巴克斯特国际公司 | 通过具有组氨酸的水性制剂在弱酸性至中性pH稳定的免疫球蛋白 |
| LT2637690T (lt) | 2010-11-11 | 2016-10-25 | Abbvie Biotechnology Ltd | Didelės koncentracijos anti-tnfalfa antikūno skystos kompozicijos |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| EP2949336B1 (en) | 2013-01-28 | 2018-09-05 | National University Corporation Kumamoto University | Stabilized protein gel preparation |
| RU2662558C2 (ru) * | 2013-07-19 | 2018-07-26 | Хексаль Аг | Способы и композиции, которые обеспечивают модуляцию иммунных ответов, связанных с введением биофармацевтического лекарственного средства |
| CN103772505B (zh) * | 2013-12-18 | 2014-10-15 | 长春博迅生物技术有限责任公司 | 一种抗体试剂保存液 |
| WO2017083627A1 (en) | 2015-11-13 | 2017-05-18 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| US20170240617A1 (en) * | 2016-02-24 | 2017-08-24 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
| WO2017170626A1 (ja) * | 2016-03-30 | 2017-10-05 | 千寿製薬株式会社 | 水性液剤 |
| US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
| EP3930757A1 (en) | 2019-03-01 | 2022-01-05 | President And Fellows Of Harvard College | Methods and compositions for protein delivery |
| CA3132521A1 (en) | 2019-03-25 | 2020-10-01 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| JP2022551622A (ja) * | 2019-10-11 | 2022-12-12 | ドクター レディズ ラボラトリーズ リミテッド | インテグリン抗体の安定な製剤 |
| BR112023023151A2 (pt) * | 2021-05-05 | 2024-01-23 | I2O Therapeutics Inc | Formulações líquidas iônicas para tratamento de doenças inflamatórias e autoimunes |
| MX2024005705A (es) | 2021-11-10 | 2024-05-24 | I2O Therapeutics Inc | Composiciones de liquidos ionicos. |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US421777A (en) * | 1890-02-18 | Straining-pot | ||
| JPH0669961B2 (ja) | 1984-09-25 | 1994-09-07 | 株式会社ミドリ十字 | 免疫グロブリンの加熱処理方法 |
| US4597966A (en) | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
| JPS62194459A (ja) | 1986-02-21 | 1987-08-26 | Sankyo Co Ltd | 固相化試薬の安定化剤 |
| JPS62244441A (ja) | 1986-04-16 | 1987-10-24 | Green Cross Corp:The | 抗体固定化担体 |
| DE3734923C1 (de) * | 1987-10-15 | 1989-01-26 | Biotest Pharma Gmbh | Verfahren zur Herstellung einer sterilen Plasmaproteinloesung,die Fibrinogen und den Gerinnungsfaktor XIII enthaelt |
| JPH03504499A (ja) | 1988-05-27 | 1991-10-03 | セントカー・インコーポレーテツド | 抗体試薬のための配合物 |
| US5945098A (en) | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
| JPH0565233A (ja) * | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
| JP2966592B2 (ja) * | 1991-07-20 | 1999-10-25 | 萩原 義秀 | 安定化されたヒトモノクローナル抗体製剤 |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| WO1993022335A1 (en) | 1992-04-30 | 1993-11-11 | Cor Therapeutics, Inc. | Stable polypeptide composition |
| JPH06189781A (ja) * | 1992-12-25 | 1994-07-12 | Mitsui Toatsu Chem Inc | 培養液中の生理活性タンパク質の安定化方法 |
| FR2708467B1 (fr) * | 1993-07-30 | 1995-10-20 | Pasteur Merieux Serums Vacc | Préparations d'immunoglobulines stabilisées et procédé pour leur préparation. |
| GB9418092D0 (en) | 1994-09-08 | 1994-10-26 | Red Cross Found Cent Lab Blood | Organic compounds |
| ES2225874T3 (es) | 1995-03-10 | 2005-03-16 | Genentech, Inc. | Activacion de receptor mediante gas. |
| AU2444899A (en) | 1998-01-22 | 1999-08-09 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
| US6488930B1 (en) * | 1999-01-15 | 2002-12-03 | Millennium Pharmaceuticals, Inc. | Anti-CCR4 antibodies and methods of use therefor |
| EP1174148A4 (en) | 1999-04-28 | 2005-05-04 | Yamanouchi Pharma Co Ltd | PARENTAL MEDICAL COMPOSITIONS CONTAINING FRAGMENTS OF HUMANIZED MONOCLONAL ANTIBODIES AND METHOD FOR STABILIZING THE SAME |
| EP1050307A1 (en) * | 1999-05-06 | 2000-11-08 | Applied Research Systems ARS Holding N.V. | CCR4 antagonists in sepsis |
| KR100754049B1 (ko) | 1999-06-25 | 2007-08-31 | 제넨테크, 인크. | 전립선암을 치료하기 위한 약제 제조에 사용되는 항-ErbB2 항체 및 조성물 |
| US7253263B1 (en) | 1999-09-30 | 2007-08-07 | Kyowa Hakko Kogyo Co., Ltd. | Complementarity determining region-grafted antibody against ganglioside GD3 and derivative of antibody against ganglioside GD3 |
| AU2228901A (en) * | 1999-12-28 | 2001-07-09 | Chugai Seiyaku Kabushiki Kaisha | Stable antibody compositions and injection preparations |
| DE60134962D1 (de) | 2000-03-03 | 2008-09-04 | Kyowa Hakko Kogyo Kk | Anti-ccr4 antikörper und fragmente davon |
| WO2002013860A1 (en) | 2000-08-11 | 2002-02-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing preparations |
| WO2003018635A1 (fr) | 2001-08-31 | 2003-03-06 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps greffes cdr humains et fragments de ces anticorps |
| EP1501870A4 (en) | 2001-11-02 | 2006-05-03 | Centocor Inc | RSV PROTEINS, ANTIBODIES, COMPOSITIONS, PROCESSES AND USES |
| KR101080021B1 (ko) | 2002-02-14 | 2011-11-04 | 추가이 세이야쿠 가부시키가이샤 | 항체함유 용액제제 |
| DK1698640T4 (da) * | 2003-10-01 | 2019-09-02 | Kyowa Hakko Kirin Co Ltd | Fremgangsmåde til stabilisering af antistof og antistofpræparat som stabiliseret opløsning. |
-
2004
- 2004-10-01 DK DK04773700.2T patent/DK1698640T4/da active
- 2004-10-01 ES ES04773700T patent/ES2562912T5/es not_active Expired - Lifetime
- 2004-10-01 HU HUE04773700A patent/HUE026793T2/en unknown
- 2004-10-01 US US10/574,016 patent/US8496930B2/en active Active
- 2004-10-01 CA CA2540848A patent/CA2540848C/en not_active Expired - Lifetime
- 2004-10-01 CN CNB2004800271879A patent/CN100522998C/zh not_active Expired - Lifetime
- 2004-10-01 EP EP15191413.2A patent/EP3006463A1/en active Pending
- 2004-10-01 SI SI200432297T patent/SI1698640T2/sl unknown
- 2004-10-01 JP JP2005514512A patent/JP4219932B2/ja not_active Expired - Lifetime
- 2004-10-01 AU AU2004277466A patent/AU2004277466C1/en active Active
- 2004-10-01 WO PCT/JP2004/014903 patent/WO2005033143A1/ja not_active Ceased
- 2004-10-01 EP EP04773700.2A patent/EP1698640B2/en not_active Expired - Lifetime
- 2004-10-01 PL PL04773700T patent/PL1698640T5/pl unknown
- 2004-10-01 PT PT47737002T patent/PT1698640E/pt unknown
-
2006
- 2006-03-31 KR KR1020067006311A patent/KR100911091B1/ko not_active Expired - Lifetime
-
2013
- 2013-06-14 US US13/918,507 patent/US9011850B2/en not_active Expired - Lifetime
-
2015
- 2015-03-18 US US14/661,510 patent/US10172790B2/en active Active
-
2016
- 2016-02-23 CY CY20161100147T patent/CY1117215T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1698640T5 (pl) | Sposób stabilizacji przeciwciała i stabilizowany preparat przeciwciała w postaci roztworu | |
| TWI367766B (en) | Immunoglobulin formulation and method of preparation thereof | |
| HUE038498T2 (hu) | Immunglobulin készítmény és elõállítási módszere | |
| EP1482984A4 (en) | REPLACEMENT ANTIBODIES AND METHOD FOR THEIR MANUFACTURE AND USE | |
| ZA200305825B (en) | Modified antibodies and methods of use | |
| IL172689A0 (en) | Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE | |
| AU2003265522A1 (en) | FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | |
| EP1648316A4 (en) | VERTEBRAL RETENTION AND CLEARANCE DEVICE AND METHOD OF USE | |
| IL169648A0 (en) | Novel structures and method of preparation | |
| AU2003277259A8 (en) | Immunoassay and method of use | |
| ZA200506790B (en) | Arylvinylazacycloalkane compounds and method of preparation and use thereof | |
| GB2414287B (en) | Peltier based freeze-thaw valves and method of use | |
| EP1578917A4 (en) | MULTIMEDIA PROTEINS AND METHODS FOR THE PRODUCTION AND USE THEREOF | |
| IL175657A0 (en) | Derivatives of dihydronepetalactone and method for preparation | |
| AU2003276844A8 (en) | Formulations of modified antibodies and methods of making the same | |
| PL1667624T3 (pl) | Układ zamknięcia i sposób wytwarzania | |
| EP1633850A4 (en) | OVR115 ANTIBODY COMPOSITIONS AND METHODS OF USE | |
| EP1631311A4 (en) | HUMANIZED ANTI-CCR2 ANTIBODIES AND METHOD OF USE | |
| GB0304555D0 (en) | Compounds and methods of manufacture | |
| EP1680489A4 (en) | EMULSION FUEL AND PROCESS FOR PREPARING THE SAME | |
| EP1549951A4 (en) | SEMAPHORIN-LIKE PROTEINS AND METHODS OF USE THEREOF | |
| EP1616020A4 (en) | ANTI-CR1 ANTIBODIES WITH REDUCED IMMUNOGENICITY AND COMPOSITIONS AND TREATMENT METHODS BASED ON THEM | |
| PL356624A1 (pl) | Wódka gatunkowa oraz sposób jej sporządzania | |
| PL356684A1 (pl) | Sposób otrzymywania preparatów dietetyczno-leczniczych oraz ich zastosowanie | |
| GB2433977B (en) | Peltier based freeze-thaw valves and method of use |